Main text {#s1}
=========

A peptidoglycan (PG) cell wall is an essential extracytoplasmic feature of most bacteria ([@bib36]); this essentiality has made its biogenesis a fruitful target for antibiotics, including vancomycin and penicillin. The cell wall is directly exposed to the extracellular milieu in Gram-positive bacteria, but is shielded in *Escherichia coli* and other Gram-negative species by a highly selective permeability barrier formed by the outer membrane (OM). The OM prevents influx of antibiotics, such as vancomycin, restricting their access to intracellular targets ([@bib7]; [@bib31]). Lipopolysaccharide (LPS) forms the surface-exposed outer leaflet of the OM and is key to the barrier function ([@bib24]; [@bib14]; [@bib23]). LPS is a glycolipid consisting of a 'lipid A' anchor within the bilayer, and a set of covalently attached distal 'core' saccharides ([@bib28]). LPS is made at the cytosolic leaflet of the inner membrane (IM) before being flipped to the periplasmic leaflet ([@bib43]). A transenvelope complex of seven [l]{.ul}ipo[p]{.ul}olysaccharide [t]{.ul}ransport proteins (LptABCDEFG) delivers LPS from the IM to the OM ([@bib32]; [@bib4]). A sub-complex of the β-barrel LptD and lipoprotein LptE resides within the OM and accomplishes the final step of inserting LPS into the outer leaflet ([@bib5]).

A recently described *lptE* mutation (*lptE613*) causes defective LPS transport and leads to increased antibiotic sensitivity ([@bib20]). To better understand the basis of the *lptE613* defect, we isolated spontaneous suppressors that restored antibiotic resistance. One such vancomycin-resistant suppressor mapped to the *waaL* gene, the product of which is an IM glycosyltransferase that attaches O-antigen (O-Ag) oligosaccharides to LPS ([@bib12]; [@bib30]). Indeed, the suppressed strain is certainly no more vancomycin sensitive than is the corresponding wild-type control ([Figure 1A](#fig1){ref-type="fig"}). However, this suppressor (*waaL15* herein) was not specific for *lptE613* or even for LPS transport defects. The *waaL15* mutation increases vancomycin resistance in strains carrying *bamB* or *bamE* null mutations that disrupt the OM barrier by causing defects in β-barrel protein assembly ([Figure 1B](#fig1){ref-type="fig"}) ([@bib29]). Moreover, *waaL15* also increases vancomycin-resistance even in the wild-type strain ([Figure 1A](#fig1){ref-type="fig"}). The suppressor does not qualitatively improve the OM barrier, since it did not increase resistance against other antibiotics ([Figure 1B](#fig1){ref-type="fig"}). So, *waaL15* provides a vancomycin-specific resistance mechanism across different strains.10.7554/eLife.05334.003Figure 1.A mutant O-antigen ligase increases vancomycin resistance.(**A**) *waaL15* provides a strain-independent increase in vancomycin resistance. Isogenic strains, differing by a point mutation in *waaL*, were plated by serial dilution on LB agar containing indicated amounts of vancomycin. (**B**) *waaL15* does not improve resistance against other antibiotics. Antibiotic discs containing either 15 μg erythromycin or 5 μg rifampin were placed on LB agar overlays inoculated with the indicated strains. Diametric zones of growth inhibition were measured across the disc. The disc diameter was 6 mm and this value represents growth at the disc.**DOI:** [http://dx.doi.org/10.7554/eLife.05334.003](10.7554/eLife.05334.003)

The domesticated *E. coli* K-12 does not produce the normal substrate (O-Ag) of WaaL ([@bib19]) and a *waaL* deletion does not suppress vancomycin sensitivity, indicating that *waaL15* is a gain-of-function mutation. Thus, the WaaL15 mutant O-Ag ligase, which contains an F332S substitution, must have an altered activity. Silver-staining of isolated LPS confirmed that WaaL15 modifies LPS with additional sugars to produce an additional glycoform (LPS\*), detected as a higher molecular-weight band that is absent in *waaL*^+^ ([Figure 2A](#fig2){ref-type="fig"}). WaaL can use two minor saccharide substrates to modify LPS in *E. coli* K-12: enterobacterial common-antigen (ECA) and colanic acid (CA). ECA-modified LPS is a minor constituent of the OM ([@bib33]; [@bib22]). Production of CA is regulated by the Rcs phospho-relay stress response system, and CA-modified LPS (called 'M-LPS') is only detectable during severe envelope stress ([@bib22]). Perhaps *waaL15* had improved the utility of one, or both, of these substrates. However, LPS silver-staining revealed that LPS\* remained detectable when we inactivated biosynthesis of ECA (*rff*), CA (*cpsG*), or both these polysaccharides (*rff cpsG*) ([Figure 2A](#fig2){ref-type="fig"}). Moreover, if we increase the amounts of a competing substrate by introducing the *rcsC137* mutation to activate expression of the genes for CA biosynthesis ([@bib11]), we actually observed lowered LPS\* abundance at the expense of increased M-LPS ([Figure 2B](#fig2){ref-type="fig"}). Notably, the decrease in LPS\* correlated with a significant reduction in vancomycin-resistance, providing evidence that LPS\* molecules directly mediate the resistance ([Figure 2C](#fig2){ref-type="fig"}). Similarly, if O-antigen biosynthesis is restored by introducing a wild-type *wbbL* gene, we observe lowered LPS\* at the expense of wild-type LPS and vancomycin resistance is reduced. We conclude that WaaL15 is able to use a new substrate and thereby generate a previously uncharacterized LPS glycoform that provides a specific mechanism for vancomycin resistance.10.7554/eLife.05334.004Figure 2.Mutant O-antigen ligase produces a novel form of LPS that is directly responsible for vancomycin resistance.(**A**) WaaL15 uses a novel substrate to produce a new LPS glycoform. Isolated LPS was resolved by SDS-PAGE and detected by silver staining. A higher molecular weight glycoform (LPS\*) appears in *waaL15* strains. Mutations that inactivate biosynthesis of ECA (*rff*::Tn*10*-66) or CA (Δ*cpsG*::*kan*) do not abrogate LPS\* production. (**B**) Overproduction of CA leads to decreased LPS\* abundance. Isogenic strains were constructed to express either wt *rcsC*^*+*^ or the *rcsC137* mutant allele that hyper-activates CA biosynthesis. LPS was isolated and visualized as in (**A**). LPS molecules modified with a one- or two- CA repeat units are labeled M-LPS and M~2~-LPS, respectively. (**C**) Reduced LPS\* levels correlate with reduced vancomycin resistance. Strains were plated by serial dilution onto LB agar supplemented with vancomycin.**DOI:** [http://dx.doi.org/10.7554/eLife.05334.004](10.7554/eLife.05334.004)

All native WaaL substrates contain carbohydrates linked to a common undecaprenyl (Und) lipid carrier. PG biosynthesis involves a disaccharide pentapeptide (DPP) linked to the same Und carrier, a molecule called lipid II ([Figure 3A](#fig3){ref-type="fig"}). To directly determine if lipid II is a substrate for WaaL15, we treated isolated LPS\* with the muralytic enzyme mutanolysin ([Figure 3A,B](#fig3){ref-type="fig"}). Digestion of purified LPS\*, but not LPS, liberated near-stoichiometric quantities of fragments that were identified by mass spectrometry as DPP or derivatives with a tetrapeptide stem ([Figure 3C](#fig3){ref-type="fig"}). Importantly, there is no evidence for cross-linked products suggesting that lipid II was the source of the LPS\* glycosylation ([@bib16]).10.7554/eLife.05334.005Figure 3.Lipid II is the glycosyl donor for LPS\*.(**A**) Structure of lipid II and schematic of peptidoglycan cleavage by mutanolysin that releases disaccharide pentapeptide ('A') and tetrapeptide ('B') species. (**B**) Treatment of *waaL15* isolated LPS with mutanolysin cleaves the LPS\* modification. (**C**) LPS\* is glycosylated with equivalent amounts of lipid II-sourced disaccharide pentapeptide and tetrapeptide. Isolated and purified LPS\* from *waaL15* and LPS from *waaL*^+^ were treated with mutanolysin and analyzed by LC-MS. Total ion chromatogram for degradation products (i and ii), and the extracted ion chromatogram for LPS\* degradation (iii) are shown. M+H and (M+2H)/2 ions corresponding to each fragment were extracted (A: 1013.3 + 507.2; B: 942.3 + 471.7).**DOI:** [http://dx.doi.org/10.7554/eLife.05334.005](10.7554/eLife.05334.005)10.7554/eLife.05334.006Figure 3---figure supplement 1.The *waaL15* mutation does not affect the PG cell wall.(**A**) The total ion chromatograms (TIC) of mutanolysin digested PG cell wall from *waaL*^+^ strain MG1210, and *waaL15* strains MG1211 are nearly identical. Disaccharide pentapeptide (DPP, fragment A) is present in mutanolysin digested LPS\* but not in the PG cell wall samples. (**B**) Mass spectra and structures for reduced DPP (fragment A) and reduced disaccharide tetrapeptide (fragment B) from mutanolysin digested LPS\*.**DOI:** [http://dx.doi.org/10.7554/eLife.05334.006](10.7554/eLife.05334.006)

There are several carboxypeptidases in the periplasm that remove the terminal D-Alanine (D-Ala) from DPP to produce the tetrapeptide derivative. Indeed, *E. coli* PG contains negligible amounts of pentapeptide stems ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). [Figure 3C](#fig3){ref-type="fig"} shows that about 50% of the LPS\* is sequestered before it can be attacked by one of these carboxypeptidases. It seemed likely that sequestration happens because the molecule is transported from the periplasm to the cell surface.

Peptide stems from adjacent peptidoglycan strands in the cell wall are cross-linked via transpeptidation between the penultimate D-Ala on one stem and a *meso*-diaminopimelic acid (*m*-DAP) residue on a nearby stem ([@bib42]). Extensive cross-linking produces a rigid macromolecular meshwork that is vital to cell wall function. Vancomycin binds and sequesters the terminal D-Ala-D-Ala residues of a pentapeptide stem in order to inhibit transpeptidation ([@bib27]). Since LPS\* was the product of DPP ligation onto LPS, then this modified glycoform should contain vancomycin binding sites. We assessed the ability of purified LPS\* to bind vancomycin in vitro. LPS\* was immobilized on a carboxymethylated dextran (CM3) chip and we used surface plasmon resonance to monitor interactions with differing concentrations of vancomycin. We were able to measure specific binding of vancomycin to LPS\* and to obtain a *K*~*d*~ = 0.48 ± 0.08 µM ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), which is comparable to a reported *K*~*d*~ for vancomycin-lipid II interactions in vesicles ([@bib1]). Clearly, LPS\* molecules include high affinity binding sites for vancomycin.10.7554/eLife.05334.007Figure 4.Mutant WaaL attaches peptidoglycan fragments to LPS.(**A**) LPS\* specifically binds vancomycin. Purified LPS\* was immobilized on a CM3 chip and varying concentrations of vancomycin were applied. Binding was measured at 25°C by surface plasmon resonance. Fitting of equilibrium signal yielded a *K*~*d*~ = 0.48 ± 0.08 µM. Standard deviation was measured for 0.6 µM and 1.2 µM and was ±1 RU. (**B**) Vancomycin binds to LPS\* at the cell surface. Live exponential-phase growing cells labeled with 1 μg/ml vancomycin-BODIPY for 10 min. Cells were spotted onto M63 minimal medium agar pads and imaged by fluorescence microscopy.**DOI:** [http://dx.doi.org/10.7554/eLife.05334.007](10.7554/eLife.05334.007)10.7554/eLife.05334.008Figure 4---figure supplement 1.SPR binding kinetics at 25°C.(**A** and **B**), Different concentrations (see legend inset in **C**) of vancomycin were passed over surfaces of total isolated LPS from *waaL*^+^ (strain MG1210) or total isolated LPS from *waaL15* (strain MG1211). (**C**), The reference subtracted kinetics after 400 s of injection. The equilibrium signals were plotted in [Figure 4A](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.05334.008](10.7554/eLife.05334.008)

The ability of LPS\* to directly bind vancomycin suggested a possible resistance mechanism, namely that vancomycin is titrated outside the cell. To test this hypothesis, we performed live cell microscopy using a fluorescent vancomycin-BODIPY. We used a wild-type strain background with an intact OM that prevents the influx of vancomycin, to avoid labeling intracellular sites of PG synthesis. Indeed, *waaL*^+^ cells could not be fluorescently labeled ([Figure 4B](#fig4){ref-type="fig"}). On the other hand, we readily detected circumferential labeling of *waaL15* bacteria, confirming the presence of accessible D-Ala-D-Ala residues at the cell surface ([Figure 4B](#fig4){ref-type="fig"}).

Several vancomycin-resistance mechanisms exist in Gram-positive bacteria, including: alterations in peptidoglycan metabolism can produce thicker cell walls ([@bib6]); and transpeptidation can be reduced to leave more free D-Ala-D-Ala residues within the established cell wall structure ([@bib35]). It was not immediately apparent to us that any of these strategies could be employed in *E. coli* since virtually all of the terminal D-Ala residues of DPP are removed either by cross-linking or by the carboxypeptidases. However, we show that the *waaL15* mechanism is comparable since it also increases the number of free D-Ala-D-Ala targets that can tie up vancomycin. Moreover, by displaying D-Ala-D-Ala at the cell surface the *waaL15* mutation titrates vancomycin away from the true drug target, in an altogether different cellular compartment. Therefore, LPS\* confers resistance by acting as a molecular decoy for vancomycin. Given that Gram-negative bacteria are inherently resistant to vancomycin this decoy mechanism may not be of clinical significance. However, the increased resistance it does confer clearly demonstrates the tremendous adaptability of bacteria under antibiotic stress.

The biosynthesis of LPS\* is remarkable. Lipid II in *E. coli* is extremely scarce, its steady-state abundance is thought to be only 1000--2000 molecules per cell ([@bib41]). Insertion of new PG is thought to occur via large multiprotein morphogenic complexes: the elongasome and the divisome, responsible for PG synthesis along the lateral cell body and at the septum, respectively. In order to overcome the scarcity of lipid II and limit its diffusion away from sites of PG growth, both complexes are suggested to include at least some of the lipid II biosynthetic enzymes, and the presumed flippases that deliver lipid II from the site of synthesis in the cytoplasm to the site of cell wall assembly in the periplasm ([@bib37]). In this model, the substrate for PG synthesis would be isolated physically from the LPS assembly pathway. LPS is inserted into the OM of each cell at a rate exceeding 70,000 molecules per minute ([@bib18]) and we approximate that one-third of LPS is modified by WaaL15 with lipid II-sourced DPP. Clearly, WaaL15 has ready access to lipid II and this is inconsistent with a model of diffusion-limited lipid II sequestered at the elongasome or divisome complexes. Recent evidence also points to wider lipid II availability ([@bib17]; [@bib34]). Our data indicate that the re-charging of the lipid carrier with new DPP must also be extremely efficient to maintain such a robust pool of PG precursor.

WaaL15 drains the available lipid II pool with no apparent detriment to cell wall integrity ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Lipid II limitation can be revealed by synthetic genetic interactions in a strain lacking the elongasome ([@bib25]), but it is not the recharging of lipid II that is limiting, rather it is the biosynthesis of DPP ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}).

In many bacteria, LPS is decorated with highly variable O-Ags that are linear polymers of repeating units of 3--6 monosaccharides ([@bib13]). In *E. coli* the multitude of different O-Ags initiate with GlcNAc, ECA also initiates with GlcNAc. In *E. coli* K-12 when colonic acid is overproduced M-LPS is made from an intitating Glc residue. The F332S mutation broadens substrate specificity of the WaaL glycosyltransferase allowing it to efficiently accept a significantly more bulky initiating MurNAc with an attached oligopeptide stem. The only other glycosyltransferase that is known to use lipid II as a substrate is PglL from *Neisseria* and the use required overproduction of the enzyme in *E. coli* ([@bib8]). It is also remarkable that we detect no OM biogenesis defect in strains carrying *waaL15*, demonstrating that the Lpt system is fully competent for the transport and assembly of LPS\* despite the addition of both unnatural sugars and peptide stems. Both LPS and PG are pathogen-associated molecular patterns (PAMPs) that potently activate innate immune responses via distinct pathways, and it seems sensible for Gram-negative bacteria to keep these entities separated. We suggest that the F332S substitution has inactivated an exclusion mechanism that prevents WaaL from utilizing the lipid II pool.

Materials and methods {#s2}
=====================

Bacterial strains and growth conditions {#s2-1}
---------------------------------------

Strains and plasmids used in this study are listed in [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"} and [Supplementary file 1C](#SD1-data){ref-type="supplementary-material"}, respectively. Strains were grown in lysogeny broth (LB, 10 g/L NaCl) or M63 minimal medium under aeration at 37°C unless otherwise noted. When appropriate, media were supplemented with kanamycin (Kan, 25 μg/ml), ampicillin (Amp, 25--125 μg/ml), tetracycline (Tet, 20 μg/ml), chloramphenicol (Cam, 20 μg/ml), vancomycin (Vanc, 65--260 μg/ml) and arabinose (Ara, 0.2% vol/vol). Kanamycin deletion-insertion mutations of *bamE, cpsG, mrcA, mrcB, lpoA* and *lpoB* were obtained from the Keio collection ([@bib2]). ECA null *rff*::Tn*10*-66 allele was obtained from strain 21566 ([@bib21]). The *ompC*::Tn*5 rcsC137* was obtained from strain SG20803 ([@bib3]). Mutant alleles were introduced by P1*vir* transduction.

Isolation and identification of *waaL15* {#s2-2}
----------------------------------------

Spontaneous suppressor mutants of strain MG1029 capable of growing on LB plates supplemented with vancomycin (140 μg/ml) were isolated; one such mutant strain was MG1088. The mutation locus conferring vancomycin-resistance in MG1088 was identified by linkage mapping using a library of random mini-Tn*10* insertions ([@bib15]). In this way, the *tdh*::Tn*10* allele was found to be approximately 70% linked to the suppressor mutation *waaL15*. The F332S mutation was then identified by PCR amplification and sequencing of the *waaL* locus. The *waaL15* mutation was moved into the NR754 wild-type strain by linkage with *tdh*::Tn*10*. In order to generate the unmarked *waaL15* strain (MG1643) and its wild-type control (MG1642), the *tdh*::Tn*10* mutation was removed from strains MG1210 and MG1211 by first introducing a linked Δ*cysE*::*kan* mutation ([@bib2]), selecting for Kan^R^ and screening for Tet^S^ transductants that were Vanc^R^ (*waaL15*) or Vanc^S^ (*waaL*^+^). The Δ*cysE*::*kan* mutation was then replaced with *cysE*^*+*^ by transduction, selection on M63 minimal medium, and screening of Vanc^R^/Vanc^S^.

Assessment of genetic linkage by co-transduction {#s2-3}
------------------------------------------------

In *E. coli*, two key PG synthases, PBP1A (*mrcA*/*ponA*) and PBP1B (*mrcB*/*ponB*), incorporate DPP from Lipid II into PG strands and also mediate transpeptidation ([@bib26]; [@bib39]). Recent evidence suggests that lipid II limitation can be revealed by synthetic genetic interactions in a strain lacking *mrcB* ([@bib25]). The genetic interaction of PG synthase mutants with *waaL15* was assessed as follows. Kan^R^-marked null alleles of *lpoA, lpoB, mrcA* and *mrcB* were introduced by P1*vir* transduction into CAG strains that carry a Tn*10* insertion in a nearby locus (see [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}). Kan^R^ Tet^R^ transductants were isolated and used to generate P1*vir* lysates. These P1*vir* were used to transduce *waaL*^*+*^ (MG1642) or *waaL15* (MG1643) strains, selecting for the Tn*10* marker. The frequency with which the Kan^R^-marked *lpo* and *mrc* alleles were co-transduced (genetically linked) was determined by replica plating on LB+Kan. Linkage was assessed in a total of 300 transductants from three independent experiments. A decrease in the cotransduction frequency in *waaL15* strains relative to *waaL*^*+*^ indicates a synthetic interaction between *waaL15* and the Kan^R^-marked allele. The synthetic interaction between *waaL15* and *mrcB*/*lpoB* null alleles was relieved in strains carrying pMurA when expression of the cloned *murA* gene (encoding the enzyme responsible for the first committed step in DPP biosynthesis) was induced with 100 μM isopropyl β-D-1-thiogalactopyranoside (IPTG). Overexpression of *murA* increases the cellular pool of UDP-MurNAc-pentapeptide and consequently also increases the pool of lipid II.

Analysis of LPS by SDS-PAGE and silver staining {#s2-4}
-----------------------------------------------

A total to 1 × 10^9^ cells from liquid culture were taken, pelleted and resuspended 0.05 ml of 'LPS Sample Buffer' (0.66 M Tris pH 7.6, 2% vol/vol sodium dodecyl sulfate \[SDS\], 10% vol/vol glycerol, 4% vol/vol β-mercaptoethanol, 0.1% wt/vol bromophenol blue). Samples were boiled for 10 min and allowed to cool to room temperature. 10 μl of Proteinase K (2.5 mg/ml, in LPS Sample Buffer) was added and samples were incubated at 56°C for 16 hr. LPS samples were then resolved by SDS-PAGE and silver stained as described previously ([@bib38]). By quantifying band density using ImageJ, we measured that LPS\* constitutes 29 ± 1% of the total LPS in *waaL15* samples.

Antibiotic disc diffusion assay {#s2-5}
-------------------------------

3 ml of molten LB Top agar (0.75% agar) was inoculated with 0.1 ml of overnight culture. The mixture was poured onto a LB agar plate (1.5% agar,) and allowed to set. Antibiotic discs (BD Sensi-Disc) were placed on the Top agar overlay and plates were incubated overnight at 37°C. The 'zone of growth inhibition' was measured across the antibiotic disc.

Fluorescence microscopy {#s2-6}
-----------------------

Overnight cultures were sub-cultured at 1:100 into fresh LB broth and grown for 1.5 hr. A 1 ml aliquot was taken, pelleted and was twice washed with 1 ml M63 medium. Cells were resuspended in 0.1 ml of M63 broth containing 1 μg/ml of vancomycin-BODIPY-FL (Life Technologies, V-34850). Cells were incubated at room temperature for 10 min and then washed twice with 1 ml M63 broth. Cells were then resuspended in 0.03 ml of M63 broth, and approximately 2 ml was spotted onto an M63-agarose pad. Cells were immediately visualized on a Nikon Eclipse 90i microscope with a Nikon Plan Apo 1.4/100 × Oil Ph3 phase objective.

LPS Purification {#s2-7}
----------------

*E. coli* MG1210 and MG1211 were each grown in 4 × 1.5 l LB medium shaking at 37°C overnight to stationary phase. The cells were harvested by centrifugation for 15 min at 5000×*g*, 4°C and washed with water (700 ml) and ethanol (40 ml) once, then twice with acetone (40 ml). After drying the cell pellet in a desiccator over night in vacuo, PCP (Phenol-Chloroform-petroleum ether) method was used for rough LPS extraction ([@bib9]).

PG Purification {#s2-8}
---------------

*E. coli* MG1210 and MG1211 were each grown in 500 ml LB medium shaking at 37°C to stationary phase (6 hr). The cell wall was isolated from the culture as described by [@bib10] and [@bib40], with modifications described below. The cells were resuspended in 20 ml phosphate buffered saline (PB, pH = 7.4) and boiled for 30 min in 80 ml 5% SDS. After the samples cooled, they were pelleted (14,000 rpm, 25°C, 1 hr) and washed six times by pelleting (14,000 rpm, 25°C, 1 hr) from 50 ml water aliquots to remove the SDS. The samples were resuspended in 1 ml PBS, treated with α-amidase (100 µl, 2 mg/ml stock in 50% glycerol, Sigma A-6380) and incubated at 37°C with shaking for 2 hr. To cleave proteins attached to the cell wall, α-chymotrypsin (100 µl, 3 mg/ml in 50% glycerol, Sigma C3142) was added, and the samples were incubated at 37°C with shaking overnight. An additional aliquot of α-chymotrypsin (100 µl) was added, and the samples were digested for an additional 4 hr. To remove the proteins, SDS was added to a final concentration of 1%, and the samples were incubated at 95°C for 1 hr. After cooling, the samples were again pelleted (14,000 rpm, 25°C, 1 hr) and washed with water repeatedly (4 × 25 ml) to remove the SDS. The final peptidoglycan (PG) samples were resuspended in 500 µl 0.02% azide and stored at 4°C.

Mutanolysin digestion and analysis {#s2-9}
----------------------------------

The PG composition was analyzed by LC/MS as previously described ([@bib16]). The method was also used to analyze LPS samples. The glycosylhydrolase mutanolysin liberated DPP and disaccharide tetrapeptide from LPS\*. Aliquots (40 µl) of PG (from MG1210 and MG1211) and LPS (from MG1210 and MG1211) were incubated with mutanolysin (10 U, 2.5 µl, 4000 U/ml, Sigma M9901, stored at −20°C in 50 mM TES, pH 7.0, 1 mM MgCl~2~, 10% glycerol) in 50 mM sodium phosphate buffer (pH 6.0, 100 μl total volume) at 37°C with shaking overnight. Another aliquot of mutanolysin (10 U, 2.5 µl) was added, and the mixture was incubated at 37°C with shaking for 3 hr. Insoluble particles were separated by centrifugation (16,000×*g*). The supernatant, containing soluble fragments, was treated with sodium borohydride (10 mg/ml in water, 100 μl) at room temperature for 30 min. Phosphoric acid (20%, 12 μl) was then added to adjust pH to ∼4. When bubbling ceased, the samples were lyophilized and re-dissolved in 25 μl water, which was analyzed on LC/MS. LC/MS analysis was conducted with ESI-MS operating in positive mode. The instrument was equipped with a Waters Symmetry Shield RP18 column (5 μm, 3.9 × 150 mm) with matching column guard. The fragments were separated using the following method: 0.5 ml/min H~2~O (0.1% formic acid) for 5 min followed by a gradient of 0% ACN (0.1% formic acid)/H~2~O (0.1% formic acid) to 20% ACN (0.1% formic acid)/H~2~O (0.1% formic acid) over 40 min.

Surface plasmon resonance analysis {#s2-10}
----------------------------------

Purified LPS (0.5 mg/ml) from strains MG1210 or MG1211 were extruded in 20 mM Tris/HCl pH 8, 150 mM NaCl and immobilized on poly-L-lysine coated CM3 Biacore chips on the active and reference channel, respectively ([@bib20]). All experiments were performed using a Biacore X100 instrument at 25°C at a flow rate of 10 μl/min with 20 mM Tris/HCl pH 8, 150 mM NaCl buffer. Different concentrations of vancomycin were injected for 400 s and dissociation was recorded for another 500 s to return to baseline. No binding was observed to the reference channel. The equilibrium signal in the difference channel was fitted to f = Bmax\*abs(x)/(Kd + abs(x)) with R^2^ = 0.88. Standard deviation was measured for 0.6 µM and 1.2 µM vancomycin in triplicate and did not exceed 1 RU.
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Thank you for sending your work entitled "A mutant *E. coli* attaches peptidoglycan to lipopolysaccharide displaying cell wall on its surface" for consideration at *eLife*. Your article has been favorably evaluated by Michael Marletta (Senior editor), a Reviewing editor, and 3 reviewers.

The Reviewing editor and the reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

This manuscript describes an unexpected property of a mutant in the O-antigen ligase *waaL* gene, which specifies a protein that connects the O-antigen with the lipid A core to form the complete LPS molecule. The authors identify an allele of *waaL* that has a different specificity as it can now incorporate a peptidoglycan fragment that can be displayed on the outer membrane of *E. coli*. The strain with the new allele of *waaL* can sequester vancomycin molecules resulting in an increase in resistance to this antibiotic.

Specific comments:

1\) The idea that redirecting peptidoglycan to the surface-exposed leaflet of Gram-negative bacteria could be a drug resistance (decoy) mechanism against vancomycin does not seem likely given all Gram-negative bacteria are already incredibly resistant to the drug. Clinically, vancomycin would never be used to treat a Gram-negative bacterial infection. Furthermore, the *E. coli* laboratory strain that this work was performed in has an inactivated O-antigen biosynthetic pathway. Actually, the MIC of their *E. coli* strain for vancomycin is \>100 higher than that of vancomycin resistant gram-positive bacterial. Thus, the authors should clarify what the increase in vancomycin resistance means in this particular case.

2\) If the *waaL15* allele is introduced into an *E. coli* that makes a complete O antigen, can WaaL still add PG to LPS?

3\) Can you please elaborate on the mutanolysin result in the context of the enzyme\'s specificity? Here, the enzyme is not cleaving within a PG chain but instead at the linkage site between DPP and the LPS acceptor and this is a bit surprising to me (although the data is clear). In K-12, the attachment site for O antigen is thought to be an outer core Heptose residue, although it has not been analyzed in detail. From the specificity of K-12 ligase (Ruan, 2012), mutanolysin must be cleaving a *β*-DPP-1,7-*α*-Hep linkage in the current situation. What is known about mutanolysin substrate specificity?

4\) In discussing the flexibility of WaaL (at the end of the Discussion), the authors should comment more directly on the existing specificity of the K-12 ligase. In *E. coli* K-12, the O antigen that K-12 used to have is built on GlcNAc (Stevenson et al., 1994, J Bacteriol, 176: 4144) using the same enzyme that initiates ECA. For M-LPS, its range of activity extends to a Glc initiated polymer (Garegg et al., 1971. Acta Chem Scan, 25: 2103). The shift to recognizing MurNAc-pentapeptide is indeed a significant change.

5\) Capture of lipid II by a non-PG glycosylation system has been reported previously ([@bib8], JBC, 283: 34596). There the authors introduced an oligosaccharyltransferase from Neisseria into K-12 and showed it could glycosylate a pilin protein acceptor with PG subunits. This heterologous system is worth mentioning in the Discussion.

10.7554/eLife.05334.011

Author response

*1) The idea that redirecting peptidoglycan to the surface-exposed leaflet of Gram-negative bacteria could be a drug resistance (decoy) mechanism against vancomycin does not seem likely given all Gram-negative bacteria are already incredibly resistant to the drug. Clinically, vancomycin would never be used to treat a Gram-negative bacterial infection. Furthermore, the* E. coli *laboratory strain that this work was performed in has an inactivated O-antigen biosynthetic pathway. Actually, the MIC of their* E. coli *strain for vancomycin is \>100 higher than that of vancomycin resistant gram-positive bacterial. Thus, the authors should clarify what the increase in vancomycin resistance means in this particular case*.

We have been careful to describe the *waaL15* phenotype as "increasing resistance" against vancomycin, taken to mean that the mutation allows strains to grow in the presence of vancomycin concentrations that would kill wild-type *waaL* equivalent strains. We have deliberately not drawn implications of this mutation to clinical resistance. However, to further clarify this issue, we have added the following two sentences: "Given that Gram-negative bacteria are inherently resistant to vancomycin this decoy mechanism may not be of clinical significance. However, the increased resistance it does confer clearly demonstrates the tremendous adaptability of bacteria under antibiotic stress."

*2) If the* waaL15 *allele is introduced into an* E. coli *that makes a complete O antigen*, *can WaaL still add PG to LPS?*

When we restore O-antigen biosynthesis in our strains (making them *wbbL*^+^), *waaL15* remains able to produce LPS\* and improve resistance against vancomycin. In these strains the absolute abundance of LPS\* is reduced, presumably because O-antigen is both a highly abundant and preferred substrate. The following sentence clarifying this point has been added: "Similarly, if O-antigen biosynthesis is restored by introducing a wild-type *wbbL* gene, we observe lowered LPS\* at the expense of wild-type LPS and vancomycin resistance is reduced."

*3) Can you please elaborate on the mutanolysin result in the context of the enzyme\'s specificity? Here, the enzyme is not cleaving within a PG chain but instead at the linkage site between DPP and the LPS acceptor and this is a bit surprising to me (although the data is clear). In K-12, the attachment site for O antigen is thought to be an outer core Heptose residue, although it has not been analyzed in detail. From the specificity of K-12 ligase (Ruan, 2012)*, *mutanolysin must be cleaving a* *β-DPP-1,7-α-Hep linkage in the current situation. What is known about mutanolysin substrate specificity?*

We agree that the mutanolysin result is surprising. However, since we don't yet know where DPP is attached to the LPS core, it is difficult for us to comment on the mutanolysin substrate specificity and we'd rather not speculate.

*4) In discussing the flexibility of WaaL (at the end of the Discussion), the authors should comment more directly on the existing specificity of the K-12 ligase. In* E. coli *K-12, the O antigen that K-12 used to have is built on GlcNAc (Stevenson et al., 1994, J Bacteriol, 176: 4144) using the same enzyme that initiates ECA. For M-LPS, its range of activity extends to a Glc initiated polymer (Garegg et al., 1971. Acta Chem Scan 25: 2103). The shift to recognizing MurNAc-pentapeptide is indeed a significant change*.

We have expanded our discussion of known WaaL substrate specificity by adding the following sentence: "In *E. coli* the multitude of different O-antigens initiate with GlcNAc, ECA also initiates with GlcNAc. In *E. coli* K-12 when colonic acid is overproduced M-LPS is made from an inititating Glc residue."

*5) Capture of lipid II by a non-PG glycosylation system has been reported previously (*[@bib8]*, JBC, 283: 34596). There the authors introduced an oligosaccharyltransferase from Neisseria into K-12 and showed it could glycosylate a pilin protein acceptor with PG subunits. This heterologous system is worth mentioning in the Discussion*.

We have amended the text to include this reference by adding this sentence: "The only other glycosyltransferase that is known to use lipid II as a substrate is PglL from Neisseria and the use required overproduction of the enzyme in *E. coli* ([@bib8])."

[^1]: Syros Pharmaceuticals Inc., Watertown, USA.
